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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not the use
of 30 mL Cerebrolysin is a safe and effective drug for improving global and cognitive function
in patients with Alzheimer’s Disease aged 50 years and older with no significant comorbidities.
STUDY DESIGN: Systematic review of three randomized controlled trials published between
2001-2006, all English language.
DATA SOURCES: Three randomized controlled trials comparing the efficacy of cerebrolysin to
placebo in the treatment of individuals ages 50 and over with AD related cognitive and global
functioning decline. All articles found using PubMed.
OUTCOMES MEASURED: Three randomized controlled studies measured improvement in
cognitive and global impairment in patients with AD using a combination of either ADAScog(clinician rated test measuring cognitive function), CIBIC+(clinician based interview of
patient to assess global change), or CGI(clinician assessment of mental deterioration). The
evaluations cover orientation, memory, language, understanding, behavior, and activities of daily
living. Evaluations with the tests mentioned were made under double-blind conditions.
RESULTS: Three randomized controlled trials were included in this review. Ruether et al.
revealed a significant effect on functional and cognitive decline with 30mL Cerebrolysin.
Panisset et al. found a significant relationship between Cerebrolysin and improved global
functioning, but no change in cognition between experimental and control groups. Alverez et al.
found insignificant effects on both cognition and global functioning.
CONCLUSIONS: The results of the three studies represent inconclusive evidence that
Cerebrolysin has significant effects on cognition and global functions in patients with AD. One
study found significant improvements in cognition and global function, but the other studies
found insignificant effects. Further studies are encouraged to develop a definitive relationship.
KEY WORDS: cerebrolysin, alzheimer’s disease, randomized
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INTRODUCTION
Alzheimer’s disease (AD) is the most common neurodegenerative disorder. It is
characterized by progressive behavioral and cognitive deficits accompanied by diffuse structural
abnormalities in the brain.4 Cerebrolysin, a peptide solution, may have the properties to stabilize
neurons and decrease amyloid production to improve cognition and global functioning in patients
with AD.
An estimated 10% of patients age 70 years and older have significant memory loss, and
over half of that population contribute the memory loss to AD.6 It is the most common cause of
dementia in the elderly and the sixth leading cause of death in the US.4,7 There are around 125
new cases per 100,000 people annually for ages 60 and over and around 3,200 new cases per
100,000 for those 70 to 79.5 An estimated 5.2 million Americans have AD in 2013.7 As the
number of Americans surviving into 80s and beyond continues to grow, and the baby boomer
generation ages, it can be assumed Alzheimer’s disease will become even more prevalent in the
future.
The estimate costs to care for an elderly patient with AD for one year are around
$50,000.6 Furthermore, the US as a whole spends close to $100 billion annually to care for
patients with AD.4 A large burden is also placed on unpaid caregivers who provided an estimated
17.5 billion hours of unpaid care in 2012, valued at more than $216 billion. The annual drug cost
for Cerebrolysin has not been identified. In 2008, 349 patients required stays in skilled nursing
facilities per 1,000 Medicare beneficiaries with Alzheimer’s and other dementias. Also, there
were 780 hospital stays per 1,000 Medicare beneficiaries for those age 65 and older with AD or
other dementias.7
AD Pathology hallmarks include amyloid plaques, neurofibrillary tangles, and diffuse
loss of neurons and synapses.5 Neuronal and synapse loss primarily in the subcortical regions of
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the brain. It is known that amyloid is toxic to neurons and synapses but the pathophysiology is
not completely understood. There is loss of cortical proteins and neurotransmitters like
acetylcholine and nicotinic cholinergic receptors.5 Also, noradrenergic and serotonergic
depletion from further degeneration subcortical brain regions.5 Symptoms include language
impairment, memory loss, agitation, anxiety, memory loss, apraxia, impaired executive function,
and sleep disorders.4,5,6
Due to the complexity of the pathologic process involved in AD the conventional
treatments to date focus on symptomatic benefit. Usual methods for treating AD consists of
acetylcholinesterase inhibitors which increase levels of Acetylcholine available at the synaptic
cleft. Conventional acetylcholinesterase inhibitors include tacrine, donepezil, rivastigmine,
and galantamine. NMDA receptor blockers, such as memantine, are used as adjunctive treatment
to stabilize cognition and function primarily in moderate and severe disease. Non-traditional
treatments include Axona, which provides an alternative fuel source of ketones for brain.
Pharmaceuticals such as trazodone, haloperidol, thioridazine, risperidone help behavioral and
sleep disorders associated with Alzheimer’s disease. All of the medications available are
centered on symptomatic relief and are effective for a limited time. The focus of current drug
development aims at stabilization strategies to delay the disease process.
The method of treatment with Cerebrolysin is being proposed because currently there is
no cure for Alzheimer’s disease; although the medications above have seemed to temporarily
improve symptoms of patients with AD. Cerebrolysin may be used as an IV alternative for the
stabilizing the disease process, relief of symptoms associated with AD, and improving activities
of daily living. This selective evidence-based medicine review evaluated three double-blind,
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randomized controlled trials comparing the efficacy of Cerebrolysin as an IV medication for
improving global and cognitive function in patients 50 years and older with AD.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not the use of 30
mL Cerebrolysin is a safe and effective drug for improving global and cognitive function in
patients with Alzheimer’s Disease aged 50 years and older with no significant comorbidities.
METHODS
The populations criteria used for selection in the studies included men and women age 50
year and older with Alzheimer’s disease. The interventions studied in the RCTs was
Cerebrolysin 30 mL IV infusion. Comparisons was made between the treatment group receiving
Cerebrolysin to the experimental group who received a visually matched Placebo. Outcomes
measured involved the efficacy and tolerability of Cerebrolysin for the treatment of AD, and
improvement in cognitive and global functioning. The types of studies included were three
randomized, double-blind, placebo controlled clinical trials.
The key words used in the searches were “Alzheimers disease,” “Cerebrolysin,” and
“randomized.” All articles were published in peer reviewed journals in the English language. The
author searched articles via PubMed and Cochrane library, and articles were selected based on
their relevance to the clinical question and inclusion of patient oriented outcomes(global
functioning and cognition). Inclusion criteria consisted of studies in which the design was
randomized, controlled, double blind, and patient-oriented outcomes(POEMs). Exclusion criteria
consisted of studies with patients under 50 years old or non-Alzheimer’s form of dementia. The
summary of statistics are reported using relative benefit increase(RBI), absolute benefit
increase(ABI), numbers needed to treat(NNT), 95% confidence interval(CI), and p-value.
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Table 1 – Demographics & Characteristics of included studies
Study

Type

# Pts

Age(yrs)

Alvarez1
(2006)

Double
blind
RCT

279

50+

Panisset2 Double
(2002)
blind
RCT

195

60+

Ruether3
(2001)

149

50-85

Double
blind
RCT

Inclusion
Criteria
diagnosis of
AD, mini
mental state
exam(MMSE)
scores from
14-25, Mod.
Ischemia
scale score
≤4, CT/MRI
within 12
months

Exclusion
W/D
Criteria
Pt with any
42
psychiatric
disorder, or
psychoactive
substance
dependence;
other
dementia;
brain
trauma,
other
neurologic
disease
diagnosis of
Pt with any
16
AD, mini
psychiatric
mental state
disorder, or
exam(MMSE) psychoactive
from 10-26,
substance
Mod.
dependence;
Ischemia
other
scale <5,
dementia;
caregiver
brain
regularly
trauma,
present,
other
CT/MRI
significant
within 12
ilness
months
diagnosis of
Pt with any
8
AD, mini
psychiatric
mental state
disorder, or
exam(MMSE) psychoactive
from 14-24,
substance
Mod.
dependence;
Ischemia
other
scale <5,
dementia;
CT/MRI
brain trauma
within 12
months

Interventions
IV infusion
of Cere
10mL, 30mL
or 60 mL
five times a
week for 4
weeks and
then two
times a week
for 8 weeks

IV infusion
of Cere 30
mL five
times a week
for 4 weeks

IV infusion
of Cere 30
mL five
times a week
for 4 weeks,
2 months
therapy free,
and repeat
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OUTCOMES MEASURED
Three randomized controlled studies measured improvement in cognitive and global
impairment in patients with AD using a combination of either ADAS-cog(clinician rated test
measuring cognitive function), CIBIC+(clinician based interview of patient to assess global
change), or CGI(clinician assessment of mental deterioration). ADAS-cog evaluations cover
orientation, memory, language, and understanding. CIBIC+ and CGI evaluations examine
activities of daily living and behavior. All outcomes measured were patient oriented outcomes
(POEMs) and evaluations were conduction at baseline and throughout the studies. The clinician
evaluated patients through a direct patient interview, and patient caregiver input was used with
CIBIC+. Evaluations with the tests mentioned were made under double-blind conditions.
RESULTS
The study conducted by Alvarez et al was a 24 week, double blind, randomized
controlled study between Cerebrolysin and a visually matched placebo. In total 65 individuals
were randomized and treated with 30 mL Cerebrolysin and 58 with placebo. The Cere group
was infused with 30mL Cerebrolysin 5 days a week for 4 weeks, and then 2 days a week for 8
weeks.1 The placebo group regimen was the same. Post-treatment phase included observing for
continued effects from previous treatment. Cognitive effects were based on ADAS-cog scores,
measure of cognition through clinician based interview and performance testing that covers
memory, orientation language, and comprehension on 70 point scale. Cerebrolysin had no
statistically significant effects on cognition with 36.9% of Cerebrolysin patients showing
improvement and 24.1% of placebo patients improving (p=.069) as displayed by Table 2. At the
study endpoint overall the patients in Cerebrolysin group performed better in cognitive testing
than baseline, while patients on placebo had deteriorated by about 2 points in ADAS-cog
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evaluations. Global functioning outcomes in this study were measured through an evaluation
with CIBIC+, which correlates behavior and activities of daily living. 60% of the patients treated
with 30 mL Cerebrolysin experienced an improvement in global functioning while only 20.7% of
placebo patients improved (Table 3). The most common adverse effects recorded throughout the
study were UTI and depression. 50.7% of subjects in the Cerebrolysin treatment group
experienced atleast one AE, while 60% of placebo subjects recorded one AE(Table 3). 2 subjects
in the Cerebrolysin group experienced serious AEs. Only one of the serious AEs proved a causal
relationship in which the patient developed bacteremia from IV administration.
Table 2: Increase in cognitive functioning in patients treated with 30 mL Cere compared to
placebo
Control event
rate (CER)
24.1%

Experimental
event rate (EER)
36.9%

Relative benefit
increase (RBI)
.5%

Absolute benefit
increase (ABI)
12.8%

Numbers needed
to treat (NNT)
8

Table 3: Increase in global function in patients treated with 30mL Cere compared to placebo
Control event
rate (CER)
20.7%

Experimental
event rate (EER)
60%

Relative benefit
increase (RBI)
1.89%

Absolute benefit
increase (ABI)
39.3%

Numbers needed
to treat (NNT)
3

Table 4: Total adverse events recorded during Alverez et al study
Control event
rate (CER)
60%

Experimental
event rate (EER)
50.7%

Relative risk
inrease (RRI)
-.016%

Absolute risk
increase (ARI)
-9.3%

Numbers needed
to harm (NNH)
-10

Ruether et al. conducted a 28 week, double blind, randomized controlled study between
Cerebrolysin and a visually matched placebo. In total 76 individuals were randomized and
treated with 30 mL Cerebrolysin and 70 with placebo. The groups were infused with 30mL
Cerebrolysin 5 days a week for 4 weeks, a 2 month treatment free interval, and repeated the same
regimen.3 The placebo group matched this regimen using normal saline. After the treatment
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phase patients were followed for continued effects. The mean difference in CGI, on an 8 point
scale, between Cerebrolysin and placebo was .42 in favor of Cere.3 Patients with CGI score less
than 5 were considered to have a positive global response to therapy. At the end of the study
45.9% of Cere treated patients showed a positive global response compared to 28.6% in the
placebo group.3 The cognitive domain, measured using ADAS-cog, proved significant effects by
Cerebrolysin. At the end of the active treatment phase a significant treatment effect was shown
with 43.7% of Cere patients compared to 15.7% of placebo patients showing improvement.3 At
28 weeks placebo pts scores had deteriorated by a mean of 1.6 points in the ADAS-cog, and
patients on Cere maintained baseline, p=.016. Correlation between global and cognitive
improvements were seen in 57.4% Cere treated patients and 27.5% of placebo patients with a p
of .006 and 95% CI of -.12/-072(table 5). Incidence of adverse effects was similar in both
groups with 43.4% in Cere group and 38.0% in placebo group have atleast one AE(Table 6). The
most common adverse effects were vertigo, headache, increased sweating, and nausea.3 Cere
caused no significant changes in vital signs and no deaths in this study.3 The absolute risk
increase was 5% with most adverse events being mild(38.2%) and similar severe AEs rates in
both groups; 1.2% less severe AEs in favor of Cerebrolysin.3
Table 5: Correlated increase in global functioning and cognitive ability with treatment of
Cere compared to placebo
Control event
rate (CER)
27.5%

Experimental
event rate (EER)
57.4%

Relative benefit
increase (RBI)
1.09%

Absolute benefit
increase (ABI)
29.9%

Numbers needed
to treat (NNT)
4

Table 6: Total adverse events recorded during the study
Control event
rate (CER)
38%

Experimental
event rate (EER)
43.4%

Relative risk
increase (RRI)
.014%

Absolute risk
increase (ARI)
5.4%

Numbers needed
to harm (NNH)
19
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Panisset et al conducted a 24 week, double blind, randomized controlled study between
Cerebrolysin and a visually matched placebo.2 In total 95 patients were randomized and treated
with Cerebrolysin, and 94 patients treated with placebo.2 The groups were infused with either
30mL Cerebrolysin or placebo on 5 days a week for 4 weeks. Following the active treatment
phase the patients were observed to determine long term efficacy. The scope of global
functioning was measured using CIBIC+, a clinician based interview assessing cognitive state,
behavior, and activities of daily living on a scale of 0(marked improvement)-7(marked
deterioration). Mean change in CIBIC+ at the end of active treatment 3.82 ± .09 for placebo and
3.88 ± .07 for Cerebrolysin.2 At Week 12, two months following end of treatment, patients
whom received Cerebrolysin had a mean difference of -.21 points on CIBIC+ in favor of
Cere(95% CI=-.5-.08, p=.033) .2 Week 12 revealed global improvement in 76% of treated
patients compared to 57% in patients on placebo, as shown in table 7. At the end of the study the
mean change in CIBIC+ was 4.46 ± .12 for placebo and 4.42 ± .12 for Cerebrolysin, which are
not statistically significant effects at 6 months.2 By the end of the study the mean difference in
CIBIC+ was .4 between the groups.2 The cognitive effects of Cerebrolysin were measured using
evaluation with ADAS-cog. Cognitive effects were minimal and insignificant at all points in the
study. The ADAS-cog mean score at week 12, 2 months after active treatment, was -.88 ± .61 for
placebo and .04 ± .64 for Cere, p value = .284.2 At the end of treatment ADAS-cog mean
difference was 1.81 points.2 The incidence of atleast one adverse event was 64% in Cerebrolysin
patients and 73% in placebo patients.2 No change in vital signs were observed with the use of
Cere and 1 death occurred ten weeks after last infusion due to pneumonia.2 The most common
AEs in patients on Cere were headache(13%) and dizziness(8%), and placebo had similar rates at
11% and 12% respectively.2
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Table 7: Increase in global functioning in patients treated with 30 mL Cere compared to
placebo
Control event
rate (CER)
57%

Experimental
event rate (EER)
76%

Relative benefit
increase (RBI)
0.33%

Absolute benefit
increase (ABI)
19%

Numbers needed
to treat (NNT)
5

Table 8: Total adverse events recorded during the study
Control event
rate (CER)
73%

Experimental
event rate (EER)
64%

Relative risk
increase (RRI)
-.12%

Absolute risk
increase (ARI)
-9%

Numbers needed
to treat (NNH)
-11

DISCUSSION
The studies covered in this review covered Cerebrolysin as a possible treatment to stop
and potentially reverse the pathologic process of AD. All studies performed and evaluated in this
review were controlled, double blind research over a significant period of time with reputable
evaluation measures.
The studies were limited by the insufficient evidence suggesting appropriate Cerebrolysin
treatment frequency and schedule. Patients between each of the three studies were subject to
different treatment schedules. Ruether et al treated patients for 8 weeks, Alvarez et al. for 12
weeks, and Panisseta et al for 4 weeks. None of the studies administered Cerebrolysin at the
same frequency throughout their respective study. Alvarez, Ruether, and Panisset et al. studied
populations of 123, 146, and 183 respectively. Each sample size was significantly large, diverse,
and studied over 6-7 month intervals.
Cerebrolysin is a peptide preparation with neurotrophic activity. It mimics the effects of
endogenous neurotrophic factors. Neurotrophic factors regulated nervous tissue functions in a
healthy environment. Natural NTFs cannot cross BBB due to complex three-dimensional
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complexion, but the active ingredient in Cerebrolysin, neuropeptides, can. Cerebrolysin induces
neuronal sprouting, neurogenesis, and neuroplasticity. The concern with this medication is that it
is extracted from pig brain and all of its components are not completely understood. It is not
currently FDA approved for the use of Alzheimer’s disease in the US although it is used in other
numerous other countries. The availability of Cerebrolysin is a concern if it progresses to
become a widely used commercial product because it is not a synthetic product. The
administration of Cerebrolysin is via IV infusion, which is another concern towards its
accessibility, long term use, and insurance coverage.
CONCLUSIONS
The evidence for Cerebrolysin as an effective treatment for AD is inconclusive. The
efficacy of Cerebrolysin was contradictory in the three studies analyzed in this review. The
effects on ADLs and behavior, measured by CIBIC+ and CGI, were significant in studies
performed by Ruether et al. and Panisset et al. The study performed by Alvarez et al. found
borderline but insignificant effects on ADLs and behavior with a p-value of .069 and wide 95%
CI.1 Evidence for improvement in cognitive function with use of Cerebrolysin in AD is also
contradictory. Studies by Alvarez et al. and Panisset et al. found insignificant effects on
cognitive functioning, measured by ADAS-cog, but Ruether et al. found significant improvement
in cognitive functioning. Further studies are encouraged to clarify the efficacy of Cerebrolysin in
AD.
The treatment regimen for all three studies was significantly different and offers an area
to focus improvement. The Ruether et al. study is the only study that found global and cognitive
improvements and incorporated a regimen of 5 days a week for 4 weeks, a 2 month treatment
free interval, and then another 5 weeks of treatment.3 Using a treatment plan that has proven to
be effective may solidify the effects of Cerebrolysin on AD patients. There have been several
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other studies performed, with the most recent in 2012. In the design of future studies the all
screening parameters used in these studies would be efficient in selecting an unbiased patient
population, using the treatment regimen stated above, and exploring the influences of increased
frequency of Cerebrolysin administration.
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